These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16954722)

  • 1. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
    Noor MA; Flint OP; Maa JF; Parker RA
    AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.
    Caumo A; Guffanti M; Perseghin G; Galli L; Lazzarin A; Luzi L; Castagna A
    AIDS; 2007 Nov; 21(17):2366-7. PubMed ID: 18090297
    [No Abstract]   [Full Text] [Related]  

  • 3. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.
    Jones SP; Waitt C; Sutton R; Back DJ; Pirmohamed M
    AIDS; 2008 Jul; 22(11):1293-8. PubMed ID: 18580608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
    Capel E; Auclair M; Caron-Debarle M; Capeau J
    Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
    Dubé MP; Shen C; Greenwald M; Mather KJ
    Clin Infect Dis; 2008 Aug; 47(4):567-74. PubMed ID: 18636958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
    Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
    Hruz PW; Yan Q; Tsai L; Koster J; Xu L; Cihlar T; Callebaut C
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1377-82. PubMed ID: 21245443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV protease inhibitors induce metabolic dysfunction in part via increased JNK1/2 pro-inflammatory signaling in L6 cells.
    Bogachus LD; Turcotte LP
    Antiviral Res; 2011 Dec; 92(3):415-23. PubMed ID: 21968131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
    Prot M; Heripret L; Cardot-Leccia N; Perrin C; Aouadi M; Lavrut T; Garraffo R; Dellamonica P; Durant J; Le Marchand-Brustel Y; Binétruy B
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3998-4004. PubMed ID: 17000748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
    Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
    AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
    Pao VY; Lee GA; Taylor S; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2010 Jan; 24(2):265-70. PubMed ID: 19890203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
    Nijland HM; L'homme RF; Rongen GA; van Uden P; van Crevel R; Boeree MJ; Aarnoutse RE; Koopmans PP; Burger DM
    AIDS; 2008 May; 22(8):931-5. PubMed ID: 18453852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
    Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
    Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.